{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:40:48Z","timestamp":1790700048727,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40263-022-00928-y","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T05:05:57Z","timestamp":1656738357000},"page":"771-783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1400-4427","authenticated-orcid":false,"given":"Erin G.","family":"Doty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Hauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Krege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Hake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"issue":"1","key":"928_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","volume":"21","author":"DB Clemow","year":"2020","unstructured":"Clemow DB, Johnson KW, Hochstetler HM, et al. Lasmiditan mechanism of action\u2014review of a selective 5-HT1F agonist. J Headache Pain. 2020;21(1):71.","journal-title":"J Headache Pain"},{"issue":"10","key":"928_CR2","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/head.13636","volume":"59","author":"M Ashina","year":"2019","unstructured":"Ashina M, Vasudeva R, Jin L, et al. Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: integrated results from 2 randomized double-blind placebo-controlled phase 3 clinical studies. Headache. 2019;59(10):1788\u2013801.","journal-title":"Headache"},{"issue":"12","key":"928_CR3","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1177\/0333102419859313","volume":"39","author":"EG Doty","year":"2019","unstructured":"Doty EG, Krege JH, Jin L, et al. Sustained responses to lasmiditan: results from post-hoc analyses of two phase 3 randomized clinical trials for acute treatment of migraine. Cephalalgia. 2019;39(12):1569\u201376.","journal-title":"Cephalalgia"},{"issue":"7","key":"928_CR4","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894\u2013904.","journal-title":"Brain"},{"issue":"2","key":"928_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40120-020-00185-5","volume":"9","author":"T Smith","year":"2020","unstructured":"Smith T, Krege JH, Rathmann SS, et al. Improvement in function after lasmiditan treatment: Post hoc analysis of data from phase 3 studies. Neurol Ther. 2020;9(2):459\u201371.","journal-title":"Neurol Ther."},{"issue":"8","key":"928_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1177\/0333102419855080","volume":"39","author":"JH Krege","year":"2019","unstructured":"Krege JH, Rizzoli PB, Liffick E, et al. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN. Cephalalgia. 2019;39(8):957\u201366.","journal-title":"Cephalalgia"},{"issue":"4","key":"928_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/00325481.2020.1860619","volume":"133","author":"DB Clemow","year":"2021","unstructured":"Clemow DB, Hochstetler HM, Dong Y, et al. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine. Postgrad Med. 2021;133(4):449\u201359.","journal-title":"Postgrad Med"},{"issue":"3","key":"928_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1468-2982.2007.01278.x","volume":"27","author":"PJ Goadsby","year":"2007","unstructured":"Goadsby PJ, Dodick DW, Almas M, et al. Treatment-emergent CNS symptoms following triptan therapy are part of the attack. Cephalalgia. 2007;27(3):254\u201362.","journal-title":"Cephalalgia"},{"issue":"7","key":"928_CR9","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/head.13544","volume":"59","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Krege JH, Lombard L, et al. Characterization of dizziness after lasmiditan usage: findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials. Headache. 2019;59(7):1052\u201362.","journal-title":"Headache"},{"issue":"3","key":"928_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0333102421989232","volume":"41","author":"M Ashina","year":"2021","unstructured":"Ashina M, Reuter U, Smith T, et al. Randomized, controlled trial of lasmiditan over four migraine attacks: FINDINGS from the CENTURION study. Cephalalgia. 2021;41(3):294\u2013304.","journal-title":"Cephalalgia"},{"issue":"11","key":"928_CR11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0333102419864132","volume":"39","author":"JL Brandes","year":"2019","unstructured":"Brandes JL, Klise S, Krege JH, et al. Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019;39(11):1343\u201357.","journal-title":"Cephalalgia"},{"issue":"24","key":"928_CR12","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222\u201332.","journal-title":"Neurology"},{"issue":"5","key":"928_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/head.14122","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Takeshima T, Homma G, et al. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache. 2021;61(5):755\u201365.","journal-title":"Headache"},{"issue":"1","key":"928_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102411430849","volume":"32","author":"P Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012;32(1):6\u201338.","journal-title":"Cephalalgia"},{"issue":"4","key":"928_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/PROM.S31392","volume":"11","author":"MJ Lainez","year":"2013","unstructured":"Lainez MJ, Garcia-Casado A, Gascon F. Optimal management of severe nausea and vomiting in migraine: improving patient outcomes. Patient Relat Outcome Meas. 2013;11(4):61\u201373.","journal-title":"Patient Relat Outcome Meas."},{"issue":"2","key":"928_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s13311-018-0615-6","volume":"15","author":"M Vila-Pueyo","year":"2018","unstructured":"Vila-Pueyo M. Targeted 5-HT1F therapies for migraine. Neurotherapeutics. 2018;15(2):291\u2013303.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"928_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.pain.2012.01.005","volume":"153","author":"DV Amrutkar","year":"2012","unstructured":"Amrutkar DV, Ploug KB, Hay-Schmidt A, et al. mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain. 2012;153(4):830\u20138.","journal-title":"Pain"},{"issue":"2\u20133","key":"928_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ejphar.2011.03.035","volume":"659","author":"A Gonzalez-Hernandez","year":"2011","unstructured":"Gonzalez-Hernandez A, Manrique-Maldonado G, Lozano-Cuenca J, et al. The 5-HT(1) receptors inhibiting the rat vasodepressor sensory CGRPergic outflow: further involvement of 5-HT(1F), but not 5-HT(1A) or 5-HT(1D), subtypes. Eur J Pharmacol. 2011;659(2\u20133):233\u201343.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"928_CR19","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","volume":"161","author":"A Labastida-Ramirez","year":"2020","unstructured":"Labastida-Ramirez A, Rubio-Beltran E, Haanes KA, et al. Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain. 2020;161(5):1092\u20139.","journal-title":"Pain"},{"issue":"8","key":"928_CR20","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/00001756-200106130-00015","volume":"12","author":"QP Ma","year":"2001","unstructured":"Ma QP. Co-localization of 5-HT(1B\/1D\/1F) receptors and glutamate in trigeminal ganglia in rats. NeuroReport. 2001;12(8):1589\u201391.","journal-title":"NeuroReport"},{"issue":"8","key":"928_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.tins.2012.04.007","volume":"35","author":"D Vecchia","year":"2012","unstructured":"Vecchia D, Pietrobon D. Migraine: a disorder of brain excitatory-inhibitory balance? Trends Neurosci. 2012;35(8):507\u201320.","journal-title":"Trends Neurosci"},{"issue":"8","key":"928_CR22","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/head.13897","volume":"60","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Vasudeva R, Krege JH, et al. Evaluation of 2-hour post-dose efficacy of lasmiditan for the acute treatment of difficult-to-treat migraine attacks. Headache. 2020;60(8):1601\u201315.","journal-title":"Headache"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00928-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T10:23:24Z","timestamp":1657103004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00928-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["928"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00928-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"16 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study and its open access publication\u00a0was sponsored\/funded\/supported by Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RBL receives research support from the NIH, FDA, as well as the National Headache Foundation and the Marx Foundation. He also receives research support from Allergan\/Abbvie, Amgen, Eli Lilly, and Electrocore. He receives personal fees as a consultant or advisor from Allergan\/Abbvie, Amgen, Biohaven Holdings, Dr. Reddy's, GlaxoSmithKline, Grifols, Impel NeuroPharma, Eli Lilly, Lundbeck, Merck, Novartis, and Teva Pharmaceuticals. He holds stock or options in Biohaven Holdings, CtrlM Health and Manistee. EGD, PMH, JHK, MK, AMH, and YD are employees and minor stockholders of Eli Lilly and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}},{"value":"The studies were carried out in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, and local regulatory requirements. The protocols were approved by an institutional review board or independent ethics committee at each study site.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent for study participation was obtained from each patient prior to the start of the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AMH, EGD, JHK, PMH, and RBL, were involved in study conception and design. MK acquired data. EGD, PMH, and YD performed data analysis. EGD, JHK, MK, PMH, RBL, and YD, provided data interpretation. AMH, EGD, JHK, MK, PMH, RBL, and YD, were involved in drafting\/revising the article. AMH, EGD, JHK, MK, PMH, RBL, and YD, have read and provided approval of the final submitted version of the manuscript and agree to be accountable for the presented work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at\n                      \n                      .","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}